Richard Coleman - Star Equity CEO Director
| STRR Stock | USD 2.42 0.14 6.14% |
Insider
Richard Coleman is CEO Director of Star Equity Holdings
| Age | 68 |
| Phone | 203 489 9500 |
| Web | https://www.starequity.com |
Richard Coleman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Coleman against Star Equity stock is an integral part of due diligence when investing in Star Equity. Richard Coleman insider activity provides valuable insight into whether Star Equity is net buyers or sellers over its current business cycle. Note, Star Equity insiders must abide by specific rules, including filing SEC forms every time they buy or sell Star Equity'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Coleman over three months ago Acquisition by Richard Coleman of 19499 shares of Star Equity subject to Rule 16b-3 | ||
Richard Coleman over six months ago Acquisition by Richard Coleman of 500 shares of Star Equity at 4.15 subject to Rule 16b-3 | ||
Richard Coleman over six months ago Acquisition by Richard Coleman of 1000 shares of Star Equity at 4.25 subject to Rule 16b-3 |
Star Equity Management Efficiency
The company has return on total asset (ROA) of (0.1013) % which means that it has lost $0.1013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1009) %, meaning that it created substantial loss on money invested by shareholders. Star Equity's management efficiency ratios could be used to measure how well Star Equity manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ryan Siurek | Biodesix | 52 | |
| Dr III | Biodesix | 53 | |
| Robert Cawthorn | Biodesix | 87 | |
| Gaetan Michel | Volitionrx | 52 | |
| John Boniface | Sera Prognostics | 63 | |
| Zvi David | DarioHealth Corp | 63 | |
| BBus CA | Intelligent Bio Solutions | 60 | |
| MBA MBA | Sera Prognostics | 70 | |
| Andrew Macan | Neuronetics | 51 | |
| Cameron MBA | Volitionrx | 54 | |
| Gary Pestano | Biodesix | 58 | |
| Stephen MS | Neuronetics | 61 | |
| Heinrich Rder | Biodesix | N/A | |
| Steven Graves | Sera Prognostics | N/A | |
| Terig Hughes | Volitionrx | 55 | |
| Mark MBA | Volitionrx | 53 | |
| Jinxiang Li | Burning Rock Biotech | 39 | |
| Sean MD | Sera Prognostics | N/A | |
| Maria JD | bioAffinity Technologies, | 69 | |
| Nadia Altomare | Sera Prognostics | 53 | |
| Dov Oppenheim | DarioHealth Corp | N/A | |
Management Performance
| Return On Equity | -0.1 | ||||
| Return On Asset | -0.1 |
Star Equity Holdings Leadership Team
Elected by the shareholders, the Star Equity's board of directors comprises two types of representatives: Star Equity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Star. The board's role is to monitor Star Equity's management team and ensure that shareholders' interests are well served. Star Equity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Star Equity's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Eberwein, Executive Board | ||
| Bob Halbert, Director Resource | ||
| Martin Shirley, Pres Solutions | ||
| Matthew Molchan, I Health | ||
| CCP CEBS, Senior Resource | ||
| Hannah Bible, Chief Officer | ||
| Scott Jarchow, I EdgeBuilder | ||
| Richard Coleman, CEO Director | ||
| Thatcher Butcher, President Inc | ||
| David Noble, Chief Officer |
Star Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Star Equity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.1 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 38.9 M | ||||
| Shares Outstanding | 3.2 M | ||||
| Shares Owned By Insiders | 29.13 % | ||||
| Shares Owned By Institutions | 10.55 % | ||||
| Number Of Shares Shorted | 27.93 K | ||||
| Price To Book | 0.21 X |
Additional Tools for Star Stock Analysis
When running Star Equity's price analysis, check to measure Star Equity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Star Equity is operating at the current time. Most of Star Equity's value examination focuses on studying past and present price action to predict the probability of Star Equity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Star Equity's price. Additionally, you may evaluate how the addition of Star Equity to your portfolios can decrease your overall portfolio volatility.